Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

TScan Therapeutics, Inc. (TCRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Presented preliminary Phase 1 clinical data from heme malignancies trial at the ASGCT 26th Annual Meeting; expect to reach recommended Phase 2 dose for two TCR-T therapy product candidates and report interim data by year-end 2023 Announced FDA clearance of fourth IND for solid tumor program – TSC-200-A0201 targeting HPV16 Closed underwritten public offering with net proceeds of approximately $134.7 million Ended 2Q 2023 with cash and cash equivalents of $208.8 million, which along with $30 million proceeds from Amgen, will fund the Company into 2026 WALTHAM, Mass., Aug 10, 2023 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor-e..."
07/24/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/24/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
06/29/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "TScan Therapeutics Announces Transition of Chief Financial Officer"
06/16/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/15/2023 4 BARBERICH TIMOTHY J (Director) has filed a Form 4 on TScan Therapeutics, Inc.
Txns: Granted 35,000 options to buy @ $2.66, valued at $93.1k
06/15/2023 4 Barton Debora (Chief Medical Officer) has filed a Form 4 on TScan Therapeutics, Inc.
Txns: Granted 430,000 options to buy @ $2.49, valued at $1.1M
06/15/2023 4 Dorton Katina (Director) has filed a Form 4 on TScan Therapeutics, Inc.
Txns: Granted 35,000 options to buy @ $2.66, valued at $93.1k
06/15/2023 4 Gruia Gabriela (Director) has filed a Form 4 on TScan Therapeutics, Inc.
Txns: Granted 35,000 options to buy @ $2.66, valued at $93.1k
06/15/2023 4 Klencke Barbara (Director) has filed a Form 4 on TScan Therapeutics, Inc.
Txns: Granted 36,524 options to buy @ $2.66, valued at $97.2k
06/15/2023 4 Silver Brian M. (CFO) has filed a Form 4 on TScan Therapeutics, Inc.
Txns: Granted 632,500 options to buy @ $2.49, valued at $1.6M
06/15/2023 4 MacBeath Gavin (CEO) has filed a Form 4 on TScan Therapeutics, Inc.
Txns: Granted 1,121,300 options to buy @ $2.49, valued at $2.8M
06/15/2023 4 ZDRAVESKI ZORAN (Chief Legal Officer) has filed a Form 4 on TScan Therapeutics, Inc.
Txns: Granted 430,000 options to buy @ $2.49, valued at $1.1M
06/15/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No. 1 to TScan Therapeutics, Inc. 2021 Equity Incentive Plan",
"Amendment No. 1 to TScan Therapeutics, Inc. 2021 Equity Incentive Plan"
06/12/2023 SC 13G ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 9.4% stake in TScan Therapeutics, Inc.
06/08/2023 SC 13G/A BlackRock Inc. reports a 3% stake in TScan Therapeutics, Inc.
06/06/2023 4 BARBERICH TIMOTHY J (Director) has filed a Form 4 on TScan Therapeutics, Inc.
Txns: Bought 37,880 shares @ $2.6284, valued at $99.6k
06/02/2023 4 Lynx1 Capital Management LP (10% Owner) has filed a Form 4 on TScan Therapeutics, Inc.
Txns: Sold 10,000 shares @ $2.5148, valued at $25.1k
Sold 15,000 shares @ $2.5201, valued at $37.8k
Sold 400 shares @ $2.5075, valued at $1k
06/02/2023 3 Lynx1 Capital Management LP (10% Owner) has filed a Form 3 on TScan Therapeutics, Inc.
06/02/2023 SC 13G Lynx1 Capital Management LP reports a 12.2% stake in TScan Therapeutics, Inc.
05/31/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement",
"Form of Pre-Funded Warrant",
"Opinion of Goodwin Procter LLP",
"TScan Therapeutics Announces Launch of Proposed Public Offering",
"TScan Therapeutics Announces Pricing of $140 Million Public Offering"
05/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors WALTHAM, Mass., May 24 , 2023 — TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment of patients with cancer, today announced that its Board of Directors has appointed Gavin MacBeath, Ph.D., as Chief Executive Officer of TScan and as a Class I Director of its Board, each effective as of May 24, 2023. Dr. MacBeath, has been serving as acting CEO since March 2023. Dr. MacBeath joined TScan in 2018 and has developed and advanced the Company's scientific platform and clinical programs. Since his appointment as acting CEO, the Company has made great progress across both..."
05/26/2023 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
05/25/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting"
05/17/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/17/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/16/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sales Agreement, by and between TScan Therapeutics, Inc. and Wedbush Securities Inc.",
"Legal Opinion of Goodwin Procter LLP"
05/16/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/16/2023 AW Form AW - Amendment Withdrawal Request:
05/15/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Entered into partnership with Amgen to identify novel targets in Crohn’s disease; TScan to receive $30 million upfront Enrolled patients in all three arms of Phase 1 hematologic malignancies study; TSC-101 progressing to second dose level Announced upcoming trial-in-progress poster presentation on 5/17 at ASGCT, followed by call at 5:30 p.m. ET Appointed Barbara Klencke, M.D., to Board of Directors Ended 1Q 2023 with cash and cash equivalents of $95.6 million, which combined with Amgen partnership extends cash runway into 3Q 2024 WALTHAM, Mass., May 10, 2023 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell the..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy